Recent News

Zantac Manufacturer Recalls Medication Due to Confirmed Contamination

Sandoz Inc. has voluntarily recalled the generic version of common medication Zantac after the medication was confirmed to be contaminated with a human carcinogen. Here, the pharmaceutical liability attorneys at The Law Offices of Peter Angelos discuss the updates to the ongoing Zantac claims.  Global health regulators recently raised concerns about the possibility that the…

Read More...

Carcinogen Found in Stomach Drug Leads to Halt in Distribution

Global health regulators have raised the alarm about the possibility that the widely used drug, Zantac, could be tainted with the same cancer-causing agent found in Valsartan earlier this year. Here, the pharmaceutical liability attorneys at The Law Offices of Peter Angelos detail the preliminary results of the FDA and EU probes. Officials are Investigating…

Read More...

Updates on Link Between Flesh-Eating Genital Infection and Diabetes Drug SGLT2 Inhibitors

A recent study investigated a potential link between a Type-2 diabetes drug and a severe and potentially fatal necrotizing fasciitis called Fournier gangrene. Here, the pharmaceutical liability attorneys at The Law Offices of Peter Angelos discuss the recent study and how SGLT2 inhibitors may potentially be linked to the development of Fournier gangrene. The First…

Read More...

FDA Includes Black Box Warning on Gout Medicine Uloric

As of February 2019, the U.S. Food and Drug Administration has stated that there is a higher risk of death associated with gout medicine Uloric (febuxostat) compared to other gout medicines. The FDA has now included a Black Box Warning for Uloric as a result of the recent findings. Here, the pharmaceutical liability attorneys at…

Read More...

Updates on Risks Surrounding Proton Pump Inhibitors (PPIs)

Proton pump inhibitors (PPIs) decrease the production of stomach acid that is responsible for the development of ulcers in the stomach, duodenum and esophagus. However, this grouping of drugs is linked to a variety of risks and side effects, and there is a growing list of lawsuits that have been filed in response to these…

Read More...

Zostavax 2019 Litigation Updates

Zostavax, a vaccine administered to protect against herpes zoster, otherwise known as shingles, is now being contested in approximately 550 cases in multidistrict litigation (MDL). Here, the Baltimore pharmaceutical liability attorneys at The Law Offices of Peter Angelos discuss updates in Zostavax litigation for 2019. Zostavax was Intended to Weaken the Shingles Virus When Zostavax…

Read More...

Updates on Safety Doubts Surrounding Nuplazid

In June of 2016, antipsychotic pharmaceutical drug Nuplazid was approved as a new method of treating psychosis in Parkinson’s patients. Since it’s release over two years ago, concern has arose regarding the drug, with some claiming it was released before more stringent testing could be completed and others concerned that the possible side effects of…

Read More...

Drug Watch — Lemtrada

The Food and Drug Administration (FDA) has recently added a warning to the prescribing information of Lemtrada, a pharmaceutical drug used to treat serious multiple sclerosis (MS) cases, after it was found to increase patients’ risk of stroke and blood vessel wall tears in the head and neck areas. Here, the pharmaceutical liability attorneys at…

Read More...

Carcinogenic Impurities in Valsartan Lead to Legal Action

On July 13th, 2018, the Food and Drug Administration (FDA) announced that several pharmaceutical companies were voluntarily recalling certain batches of valsartan-containing blood pressure medication after it was found that they may contain carcinogenic impurities. Now, two individuals have filed a lawsuit in New York federal court and are seeking other individuals who have been…

Read More...

The Opioid Crisis by The Numbers

Read More...